Newman Dignan & Sheerar’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$912K Hold
9,370
– – 0.17% 91
2026
Q2
$840K Sell
9,370
-200
-2% -$16.5K 0.16% 100
2026
Q1
$758K Sell
9,570
-500
-5% -$40.4K 0.16% 98
2025
Q4
$827K Buy
10,070
+298
+3% +$23.1K 0.17% 99
2025
Q3
$683K Sell
9,772
-700
-7% -$47.3K 0.15% 106
2025
Q2
$671K Sell
10,472
-400
-4% -$24.8K 0.15% 102
2025
Q1
$690K Hold
10,872
– – 0.19% 93
2024
Q4
$723K Sell
10,872
-550
-5% -$37.9K 0.19% 95
2024
Q3
$781K Buy
11,422
+500
+5% +$34.6K 0.19% 95
2024
Q2
$708K Sell
10,922
-360
-3% -$22.8K 0.18% 102
2024
Q1
$730K Sell
11,282
-1,404
-11% -$91.4K 0.2% 99
2023
Q4
$835K Buy
12,686
+1,500
+13% +$87.2K 0.25% 92
2023
Q3
$638K Sell
11,186
-1,625
-13% -$99.1K 0.21% 99
2023
Q2
$785K Sell
12,811
-440
-3% -$27.5K 0.24% 95
2023
Q1
$832K Buy
13,251
+50
+0.4% +$3.22K 0.27% 87
2022
Q4
$838K Hold
13,201
– – 0.28% 86
2022
Q3
$778K Hold
13,201
– – 0.12% 85
2022
Q2
$762K Hold
13,201
– – 0.26% 90
2022
Q1
$819K Sell
13,201
-200
-1% -$12.2K 0.16% 88
2021
Q4
$954K Buy
13,401
+200
+2% +$14.5K 0.29% 86
2021
Q3
$988K Hold
13,201
– – 0.29% 75
2021
Q2
$1.02M Hold
13,201
– – 0.34% 71
2021
Q1
$974K Buy
13,201
+460
+4% +$34.8K 0.35% 72
2020
Q4
$894K Sell
12,741
-1,200
-9% -$76K 0.14% 71
2020
Q3
$789K Buy
+13,941
New +$819K 0.33% 73
2019
Q3
– Sell
-15,365
Closed -$822K – 156
2019
Q2
$822K Buy
+15,365
New +$797K 0.37% 71
2018
Q3
– Sell
-14,115
Closed -$772K – 158
2018
Q2
$772K Hold
14,115
– – 0.05% 63
2018
Q1
$689K Sell
14,115
-476
-3% -$24.3K 0.35% 73
2017
Q4
$688K Hold
14,591
– – 0.34% 76
2017
Q3
$729K Buy
14,591
+54
+0.4% +$2.56K 0.39% 69
2017
Q2
$664K Hold
14,537
– – 0.37% 78
2017
Q1
$615K Sell
14,537
-260
-2% -$10.9K 0.27% 82
2016
Q4
$574K Buy
+14,797
New +$597K 0.35% 80
2016
Q3
– Sell
-16,897
Closed -$625K – 149
2016
Q2
$625K Buy
+16,897
New +$663K 0.39% 73
2016
Q1
– Sell
-22,022
Closed -$1.11M – 137
2015
Q4
$1.11M Sell
22,022
-103
-0.5% -$5.09K 0.79% 38
2015
Q3
$1.01M Sell
22,125
-2,500
-10% -$140K 0.65% 34
2015
Q2
$1.44M Sell
24,625
-1,600
-6% -$91.5K 1.03% 28
2015
Q1
$1.45M Sell
26,225
-1,625
-6% -$87.8K 1.03% 28
2014
Q4
$1.4M Sell
27,850
-475
-2% -$23.2K 0.84% 30
2014
Q3
$1.31M Buy
+28,325
New +$1.28M 0.98% 29
2014
Q2
– Sell
-31,525
Closed -$1.31M – 147
2014
Q1
$1.31M Sell
31,525
-3,150
-9% -$135K 0.93% 32
2013
Q4
$1.28M Sell
34,675
-1,275
-4% -$45.7K 0.9% 31
2013
Q3
$1.26M Sell
35,950
-50
-0.1% -$1.66K 0.98% 29
2013
Q2
$1.04M Buy
+36,000
New +$1.02M 0.08% 37

Other funds holding PBE

Newman Dignan & Sheerar's PBE Position: Q3 2026 in Review

Newman Dignan & Sheerar held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q3 2026 at 9,370 shares worth $912K. The position accounts for 0.17% of the portfolio, ranked #91.

Newman Dignan & Sheerar first reported a position in PBE in Q2 2013 and has held it in 44 quarters since. The position peaked at $1.45M in Q1 2015. 110 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

  • Newman Dignan & Sheerar held 9,370 shares of Invesco Biotechnology & Genome ETF worth $912K as of Q3 2026.
  • Newman Dignan & Sheerar left its Invesco Biotechnology & Genome ETF share count unchanged in Q3 2026.
  • Invesco Biotechnology & Genome ETF made up 0.17% of Newman Dignan & Sheerar's portfolio in Q3 2026, its #91 holding.
  • Newman Dignan & Sheerar first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 44 quarters since.
  • Newman Dignan & Sheerar's Invesco Biotechnology & Genome ETF position peaked at $1.45M in Q1 2015.
  • 110 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on Newman Dignan & Sheerar's 13F filing for Q3 2026, filed 21 Oct 2026.